Clinical trials deliver medical breakthroughs – but how do they happen?
Clinical trials deliver medical breakthroughs – but how do they happen? Prof. Dr Martina Brueckmann talks about her role getting new drugs to trial.
Search
Translational Medicine & Clinical Pharmacology
We connect the right patient with the right drug on the right dosing schedule using data science methods from pharmacometrics to systems pharmacology.
We’re looking for SAP developers to join our Global IT Department
Are you looking to take the next step in your career? Our global IT department has new SAP developer positions available!
Thinking differently could eradicate some areas of retinal disease
Retinal disease could be eradicated by thinking differently. Degenerative eye conditions can be cured with a patient-first approach, says Dr Victor Chong.
Leticia develops product medical strategies
Leticia develops product medical strategies at Boehringer Ingelheim. For more talent insights, visit our Careers Page.
Boehringer Ingelheim unveils groundbreaking Research and Development space in St. Joseph, Mo.
Boehringer Ingelheim unveils groundbreaking Research and Development space in St. Joseph, Mo.
More Green | Sustainable Development | Boehringer Ingelheim US
Our MORE GREEN pillar encompasses initiatives that consider many different aspects: adopting measures to avoid water and air pollution, & much more.
Cardio-Renal-Metabolic diseases
Cardio-Renal-Metabolic diseases
Mental Health disorders
Mental Health disorders
Sustainable Development for Generations | Boehringer Ingelheim US
At BI, Sustainable Development – For Generations is about a journey. One that started in 1885 and one that we hope, and believe, will never end.
Media Overview
Media Overview
Mental Disorders
Mental Disorders
Pre-Employment
Pre-Employment
Transition to renewable energy signals a broader commitment to environmental sustainability
Transition to renewable energy signals a broader commitment to environmental sustainability
FDA accepts Jardiance sNDA for T2D in children 10 and older
The US FDA has accepted a supplemental New Drug Application for Jardiance® (empagliflozin) tablets as a potential treatment for children 10 years and older with type 2 diabetes
U.S. FDA approves Jardiance® (empagliflozin) tablets to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease
U.S. FDA approves Jardiance® (empagliflozin) tablets to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease
1885-1948: Innovative Beginnings | Boehringer Ingelheim US
Click here to read an in-depth history of Boehringer Ingelheim's formation, early days and what led us to being the global pharmaceutical company of today.
Clinical Pharmacology
Boehringer Ingelheim is proud to offer a new two-year fellowship within Clinical Pharmacology. Click here to find out more.
Sant Cugat del Vallès (Barcelona)
Boehringer Ingelheim settled in Spain in 1952. For almost 70 years, t
When Passion Starts as a Family Value and Continues as a Work Value
Discover who inspires members of our LatinX Business Resource Group.
Vampire Bats & Rabies: A Potential New Threat | Boehringer Ingelheim US
Read more on the emerging threat of rabid vampire bats in the Southern US. Helping prevent this disease preserves the lives of livestock worldwide.
Livestock
Livestock
Kobe
The Kobe Pharma Research Institute takes part in the global research and development activities for human pharmaceuticals.
HEARTGARD Plus Save A Heart Initiative | Boehringer Ingelheim US
See how Boehringer Ingelheim, the maker of HEARTGARD Plus, is flying at risk dogs to new homes across the US to celebrate Heartworm Disease Awareness Month
Driving innovation through diversity and inclusion
Driving innovation through diversity and inclusion